Revolutionizing Genetic Testing, Recombine Named As One Of Six Biotech Startups To Watch
Founded just three years ago, venture-backed bioinformatics startup Recombine already has 50 employees and $3.5 million in revenue. Success in the biomedical world used to mean a many-years-long slog and a small fortune to bring a treatment, device or diagnostic to market. That paradigm is beginning to shift.
“The biotech model is changing,” said Alessandro Bisignano, Recombine’s CEO. “Because genomics is becoming cheaper, it’s becoming a data science instead of a molecular science.”
Crain’s chose six of the hottest biotech startups operating in the city based on their potential to attack very large markets. But they also stand out for the ways they’re going about their challenges. Companies like Recombine and Celmatix are software-driven and leaner, less risky and less capital-intensive than their forebears. Using genomics, they evaluate fertility and pregnancy, offering patients and physicians new ways to look at risk. Other companies are developing new technologies, aided by informatics, to attack age-old scourges.Read the full article on Crain's New York